Third Harmonic Bio Inc. (NASDAQ:THRD) — Market Cap & Net Worth
Market Cap & Net Worth: Third Harmonic Bio Inc. (THRD)
Third Harmonic Bio Inc. (NASDAQ:THRD) has a market capitalization of $242.79 Million ($242.79 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15882 globally and #3700 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Third Harmonic Bio Inc.'s stock price $5.38 by its total outstanding shares 45127800 (45.13 Million). Review THRD current and long-term liabilities to assess the company's total debt and financial obligations.
Third Harmonic Bio Inc. Market Cap History: 2022 to 2025
Third Harmonic Bio Inc.'s market capitalization history from 2022 to 2025. Data shows change from $194.05 Million to $242.79 Million (-32.61% CAGR).
Index Memberships
Third Harmonic Bio Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.01% | #427 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1543 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.01% | #217 of 263 |
Weight: Third Harmonic Bio Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Third Harmonic Bio Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Third Harmonic Bio Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of THRD by Market Capitalization
Companies near Third Harmonic Bio Inc. in the global market cap rankings as of June 18, 2026.
Key companies related to Third Harmonic Bio Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Third Harmonic Bio Inc. Historical Marketcap From 2022 to 2025
Between 2022 and today, Third Harmonic Bio Inc.'s market cap moved from $194.05 Million to $ 242.79 Million, with a yearly change of -32.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $242.79 Million | -47.72% |
| 2024 | $464.37 Million | -6.20% |
| 2023 | $495.05 Million | +155.12% |
| 2022 | $194.05 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Third Harmonic Bio Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $242.79 Million USD |
| MoneyControl | $242.79 Million USD |
| MarketWatch | $242.79 Million USD |
| marketcap.company | $242.79 Million USD |
| Reuters | $242.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Third Harmonic Bio Inc.
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibit… Read more